# Becton Dickinson (Netherlands)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/becton-dickinson-netherlands/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 2 |
| Citations | 1,122 |
| City | Breda |
| Country | NL |
| Description | Becton Dickinson (Netherlands) is a research organisation in Breda, NL. OpenAlex records 82 works and 1,122 citations for it. 41 researchers list it as their most recent affiliation. |
| Homepage | http://www.bd.com/nl/ |
| OpenAlex ID | https://openalex.org/I4210150333 |
| Researchers | 41 |
| ROR ID | https://ror.org/03qdj6986 |
| Type | company |
| Works | 82 |

## University papers

- [Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment](https://scholariq.org/papers/economic-burden-of-adult-patients-with-moderate-to-severe-atopic-dermatitis/)
- [P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK](https://scholariq.org/papers/p944-real-world-patient-characteristics-and-survival-outcomes-of-lenalidomide/)
- [P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA](https://scholariq.org/papers/p979-patient-reported-outcomes-for-teclistamab-versus-real-world-physician-s/)
- [P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison](https://scholariq.org/papers/p-244-teclistamab-versus-belgian-real-world-clinical-practice-in-triple-class/)
- [Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis](https://scholariq.org/papers/inpatient-vs-outpatient-treatment-management-with-teclistamab-in-relapsed-and/)
- [Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries](https://scholariq.org/papers/health-loss-due-to-market-access-delays-and-reimbursement-restrictions-in-first/)
- [PCN44 - FIRST-LINE TREATMENT EFFICACY IN EGFR-POSITIVE NON-SMALL CELL LUNG CANCER: A NETWORK META-ANALYSIS](https://scholariq.org/papers/pcn44-first-line-treatment-efficacy-in-egfr-positive-non-small-cell-lung-cancer/)

## University researchers

- [Kirsten van Nimwegen](https://scholariq.org/researchers/kirsten-van-nimwegen/)

## University top topics

Showing 8 of 23.

- [Seismic Imaging and Inversion Techniques](https://scholariq.org/topics/seismic-imaging-and-inversion-techniques/)
- [Mesoporous Materials and Catalysis](https://scholariq.org/topics/mesoporous-materials-and-catalysis/)
- [Concrete and Cement Materials Research](https://scholariq.org/topics/concrete-and-cement-materials-research/)
- [Zeolite Catalysis and Synthesis](https://scholariq.org/topics/zeolite-catalysis-and-synthesis/)
- [Carcinogens and Genotoxicity Assessment](https://scholariq.org/topics/carcinogens-and-genotoxicity-assessment/)
- [Hair Growth and Disorders](https://scholariq.org/topics/hair-growth-and-disorders/)
- [Sphingolipid Metabolism and Signaling](https://scholariq.org/topics/sphingolipid-metabolism-and-signaling/)
- [Nanomaterials and Printing Technologies](https://scholariq.org/topics/nanomaterials-and-printing-technologies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.